Daiichi Sankyo and AstraZeneca are initiating a global Phase 3 trial to compare Enhertu (fam-trastuzumab deruxtecan-nxki) to Kadcyla (ado-trastuzumab emtansine, also called T-DM1) as adjuvant therapy in patients with HER2-positive early breast cancer, who remain at high risk of recurrence after neo-adjuvant therapy. These two types of therapy— adjuvant and neo-adjuvant — address different aspects of cancer treatment. Neo-adjuvant therapy aims to make tumors easier to remove by shrinking them before surgery. Adjuvant treatment aims to eradicate…
You must be logged in to read/download the full post.
The post Phase 3 Trial to Compare Enhertu to Kadcyla in HER2-Positive, High Risk Patients appeared first on BioNewsFeeds.